[Use of perindopril in the treatment of patients with diabetic retinopathy].
There have been recent data on an important role of the rennin-angiotensin system (RAS) and its major effector--angiotensin-converting enzyme (ACE) in the pathogenesis of diabetes mellitus and its complications. The treatment for diabetes mellitus with ACE inhibitors (ACEI) has received wide recognition. By lowering blood pressure, ACEI improves endothelial function, positively affect carbohydrate metabolism, and exerts a nephroprotective effect. However, the role of ACEI in the treatment of diabetic retinopathy (DR) remains to be studied. This paper presents the results of a comprehensive clinicofunctional study of 36 patients with preproliferative DR before and after treatment with the ACEI perindopril. The agent has been found to have a positive effect on visual functions, retinal electrogenesis, and the state of the blood-retinal barrier.
Neroev
V V
VV
Riabina
M V
MV
Okhotsimskaia
T D
TD
Zueva
M V
MV
Tsapenko
I V
IV
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001813:Blood-Retinal Barrier; D003627:Data Interpretation, Statistical; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy*; D004596:Electroretinography; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril